This NDC is on FDA's drug shortage list (posted Mar 13, 2023)

Reported reason: Demand increase for the drug

Product Information

METHOTREXATE 50 MG/2 ML VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $1.2771 per ML under NDC 00143951910. Its NADAC has been published 233 times since Apr 11, 2018.

FDA first approved this application on Sep 16, 1986. Its Orange Book therapeutic-equivalence code is AP.

METHOTREXATE 50 MG/2 ML VIAL

Methotrexate
$1.2771per ML

Strength

25 mg/mL

NDC

00143951910

Classification

Generic

Dosage Form

SOLUTION

Route

INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS

Effective Date

11/18/2026

Active Ingredients

METHOTREXATE

Approval Type

Generic (ANDA)

FDA Application

ANDA089340

FDA Approved

9/16/1986

TE Code

AP

On Market Since

10/10/2017

Pharmacological Classes

Folate Analog Metabolic Inhibitor
Folic Acid Metabolism Inhibitors

Price Statistics

The NADAC for METHOTREXATE 50 MG/2 ML VIAL has been published 233 times since Apr 11, 2018, and over the history we have for it it has declined 25.6%. The table below summarizes its recorded NADAC range and movement.

Current price$1.2771 per ML
All-time high$1.7314 (Jul 11, 2018)
All-time low$1.1511 (Jan 17, 2024)
52-week high$1.3332
52-week low$1.2060
Median price$1.3497
Average price$1.3604
Largest weekly change+14.9% (Feb 21, 2024)
Weeks tracked233
Tracking sinceApr 11, 2018

Price History

1W

+1.3%

1M

+3.2%

3M

+3.2%

6M

+3.6%

1Y

-4.2%

3Y

-5.5%

5Y

-13.3%

All

-25.6%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methotrexate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of METHOTREXATE 50 MG/2 ML VIAL?

The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 50 MG/2 ML VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $1.2771 per ML (NDC 00143951910), effective Nov 18, 2026.

How has the price of METHOTREXATE 50 MG/2 ML VIAL changed over time?

Over the history we have for it, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has declined 25.6%. It has been tracked across 233 weekly CMS publications since Apr 11, 2018.

What are the highest and lowest recorded NADAC prices for METHOTREXATE 50 MG/2 ML VIAL?

Since Apr 11, 2018, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has ranged from a low of $1.1511 (Jan 17, 2024) to a high of $1.7314 (Jul 11, 2018), with a median of $1.3497 per ML.

Are there cheaper alternatives to METHOTREXATE 50 MG/2 ML VIAL?

No other NADAC-published product currently shares the active ingredient and strength of METHOTREXATE 50 MG/2 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures METHOTREXATE 50 MG/2 ML VIAL?

METHOTREXATE 50 MG/2 ML VIAL (NDC 00143951910) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.

Is METHOTREXATE 50 MG/2 ML VIAL in shortage?

Yes — NDC 00143951910 is currently listed in FDA's drug shortage database (posted Mar 13, 2023). Reported reason: Demand increase for the drug.